Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 3/20 | 0.91 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyruvate SCHEMBL148220 | 0.95 | — | — | |
| Pyruvate SCHEMBL18226 | 0.91 | — | — | |
| Pyruvate SCHEMBL598199 | 0.91 | — | — | |
| Pyruvate SCHEMBL1331761 | 0.91 | — | — | |
| Pyruvate SCHEMBL1332958 | 0.91 | — | — | |
| Pyruvate SCHEMBL1332703 | 0.91 | — | — | |
| Pyruvate SCHEMBL6743471 | 0.91 | CA4 (0.91) | CA4CA1TSHRTHPOFAHD1 | |
| Pyruvate SCHEMBL7936306 | 0.91 | CA4 (0.91) | CA4CA1TSHRTHPOFAHD1 | |
| Pyruvate SCHEMBL3745552 | 0.91 | CA4 (0.91) | CA4CA1TSHRTHPOFAHD1 | |
| Pyruvate SCHEMBL597153 | 0.91 | CA4 (0.91) | CA4CA1TSHRTHPOFAHD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118556088-A | Thermally debondable adhesive | 3M创新有限公司 | 2024-08-27 | — | — | CN | claimed |
| CN-104998264-B | Methods and compositions for treating mammalian diseases and wounds caused by peroxynitrite overexpression | 北方细胞制药公司 | 2020-09-15 | — | — | CN | claimed |
| US-20180338936-A1 | Methods and Compositions for the Treatment and Prevention of Allergic Rhinitis | MARTIN ALAIN (US) | 2018-11-29 | — | — | US | claimed |
| US-9675569-B2 | Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells | CELLULAR SCIENCES, INC. | 2017-06-13 | — | — | US | claimed |
| US-20160022616-A1 | Method for Treating a Pulmonary Disease State in Mammals by Up Regulating Indigenous in vivo Levels of Inflammatory Agents in Mammalian Cells | CELLULAR SCIENCES, INC. | 2016-01-28 | — | — | US | claimed |
| EP-1855721-B1 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES AND INJURIES CAUSED BY THE OVER-EXPRESSION OF PEROXYNITRITE | NORTH CELL PHARMACEUTICAL INC (US) | 2014-09-10 | — | — | EP | claimed |
| WO-2013187891-A1 | METHOD FOR TREATING A PULMONARY DISEASE STATE IN MAMMALS BY UP REGULATING INDIGENOUS IN VIVO LEVELS OF INFLAMMATORY AGENTS IN MAMMALIAN CELLS | MARTIN ALAIN (US) | 2013-12-19 | — | — | WO | claimed |
| US-20130018334-A1 | Biodegradable wound care products with biocompatible artificial skin treatment and healing accelerator | NORTHCELL PHARMACEUTICAL INC. | 2013-01-17 | — | — | US | claimed |
| US-8211943-B2 | Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells | CELLULAR SCIENCES, INC. | 2012-07-03 | — | — | US | claimed |
| US-8114907-B2 | Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells | CELLULAR SCIENCES INC (US) | 2012-02-14 | — | — | US | claimed |
| EP-2187738-A1 | METHOD FOR TREATING A PULMONARY DISEASE STATE IN MAMMALS BY UP OR DOWN REGULATING INDIGENOUS IN VIVO LEVELS OF INFLAMMATORY AGENTS IN MAMMALIAN CELLS | Cellular Sciences, Inc. (US) | 2010-05-26 | — | — | EP | claimed |
| WO-2009020582-A1 | METHOD FOR TREATING A PULMONARY DISEASE STATE IN MAMMALS BY UP OR DOWN REGULATING INDIGENOUS IN VIVO LEVELS OF INFLAMMATORY AGENTS IN MAMMALIAN CELLS | CELLULAR SCIENCES, INC. (US) | 2009-02-12 | — | — | WO | claimed |
| US-20090041738-A1 | Method for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of inflammatory agents in mammalian cells | CELLULAR SCIENCES, INC. | 2009-02-12 | — | — | US | claimed |
| US-20090041739-A1 | Method for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of inflammatory agents in mammalian cells | CELLULAR SCIENCES, INC. | 2009-02-12 | — | — | US | claimed |
| EP-1855721-A1 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES AND INJURIES CAUSED BY THE OVER-EXPRESSION OF PEROXYNITRITE | North Cell Pharmaceutical, Inc. (US) | 2007-11-21 | — | — | EP | claimed |
| WO-2006086643-A1 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES AND INJURIES CAUSED BY THE OVER-EXPRESSION OF PEROXYNITRITE | NORTH CELL PHARMACEUTICAL, INC. (US) | 2006-08-17 | — | — | WO | claimed |
| US-20050197397-A1 | Method and composition for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite | NORTH CELL PHARMACEUTICAL | 2005-09-08 | — | — | US | claimed |
| US-12611389-B1 | Compositions and methods to reduce or eliminate nasal biofilms and mucus barriers allowing sodium pyruvate to increase the synthesis of nitric oxide and eliminate nasal infections and their toxins that cause lung, nerve and brain damage | CELLULAR SCIENCES, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20050197397-A1 | Method and composition for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite | NORTH CELL PHARMACEUTICAL | 2005-09-08 | — | — | US | disclosed |
| EP-0031805-B1 | HARD BODY, ESPECIALLY HARD METAL WEARING PART, AND PROCESS FOR ITS PRODUCTION | VEREINIGTE EDELSTAHLWERKE AKTIENGESELLSCHAFT (VEW) (AT) | 1984-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611389-B1 | Compositions and methods to reduce or eliminate nasal biofilms and mucus barriers allowing sodium pyruvate to increase the synthesis of nitric oxide and eliminate nasal infections and their toxins that cause lung, nerve and brain damage | CX3CR1, CHRM3, CHRM2 | CA4 1950/4885CA1 1625/4885TSHR 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.